Human Placental Collagen Compositions for Tissue Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current collagen compositions for tissue augmentation or replacement lack desirable physical properties, leading to limitations in their application, and there is a need for compositions with reduced contamination and toxicity, as well as improved durability and injectability.
Innovation Solution
Development of base-treated, detergent-treated telopeptide collagen compositions with high collagen content, substantially free from cellular and protein contaminants, and incorporating stem cells such as placental stem cells, which can be formulated into various shapes and administered using specific techniques to enhance tissue repair and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional collagen compositions are used for tissue augmentation, then they can provide basic structural support, but they lack desirable physical properties, show contamination by cellular and protein contaminants, and exhibit higher toxicity
Solution Approach 1:
The patent applies extraction by removing contaminating proteins (fibronectin, laminin, cytokines, growth factors) and cellular debris from the collagen composition through purification processes. This results in a highly purified collagen product with at least 90% collagen content, directly addressing the contamination issue while maintaining the structural support function.
Solution Approach 2:
The patent changes the compositional parameters of the collagen by controlling the presence and concentration of specific proteins. By adjusting the purification level to achieve at least 90% collagen content and controlling fibronectin and laminin levels at less than 1% each, the patent optimizes both purity and biocompatibility, resolving the contradiction between maintaining structural integrity and reducing contamination.
2Reliability
If collagen compositions are prepared with high collagen content, then purity is improved, but the complexity of preparation and formulation increases
Solution Approach 1:
The patent applies preliminary action by pre-formulating the collagen composition with stem cells and growth factors during the manufacturing process. This preliminary incorporation ensures that the high-purity collagen (at least 90%) is already optimized for its intended tissue regeneration function, reducing the need for complex post-preparation steps and simplifying the overall process despite the high purification requirements.
Solution Approach 2:
The patent creates a composite material system by combining highly purified collagen with stem cells and growth factors in a controlled formulation. This composite approach allows the collagen to serve as a purified structural framework while the added biological components provide regenerative functions, achieving high purity without sacrificing functional complexity.
3Strength
If collagen compositions are formulated for tissue augmentation, then they can provide structural support, but they lack improved durability and injectability
Solution Approach 1:
The patent applies parameter changes by controlling the physical and chemical properties of the collagen composition, including its rheological characteristics. By adjusting parameters such as collagen concentration, cross-linking degree, and molecular weight distribution, the patent achieves a balance between durability (structural strength) and injectability (flow properties), allowing the composition to be administered via injection while maintaining long-term structural support.
Solution Approach 2:
The patent applies dynamics by formulating the collagen composition to exhibit dynamic rheological properties that allow it to flow during injection but maintain structural integrity after implantation. The composition can transition from a injectable state to a stable, durable structure in situ, resolving the contradiction between ease of administration and long-term strength.
Data Source
AI summary
The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.